Houston talk. Take it with you.Free KSEV Radio appGet for iPhoneGet for Android
Skip to content
KSEV 700 AM KSEV 700 AMThe Voice of Texas

FROM SRN NEWS

Drug developer Lycia Therapeutics targets $938 million valuation in US IPO

SHARE X Facebook

Oct 20 (Reuters) – Drug developer Lycia Therapeutics said on Tuesday it was targeting a valuation of up to $937.7 million in its US initial public offering, as biotech companies flock to the IPO market.

The South San Francisco, California-based company is seeking to raise up to $264.6 million in the IPO by offering 14.7 million shares priced between $16 and $18 apiece.

The healthcare sector has anchored the fall IPO window this year in an otherwise lackluster market as investors become selective in a higher rate environment.

Drug developers City Therapeutics and Nvidia-backed Iambic Therapeutics went public in New York last week.

Jefferies, TD Cowen, Evercore ISI, and Guggenheim Securities are joint book-running managers. Lycia will list on the Nasdaq under the symbol “LYCA”.

(Reporting by Arasu Kannagi Basil in Bengaluru; Editing by Devika Syamnath)

Brought to you by www.srnnews.com

SRN News — View the original story at SRNNews.com.

LIVE Best of Press Box Tap play to listen
0:00 0:00
Show